| JS212 Combination Therapies in Metastatic Colorectal Cancer (NCT07503756) | Shanghai Junshi Bioscience Co., Ltd. | 2026-04-25 |
| Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors (NCT07480733) | Shanghai Junshi Bioscience Co., Ltd. | 2026-04-23 |
| JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study (NCT07518160) | Shanghai Junshi Bioscience Co., Ltd. | 2026-04-21 |
| A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma (NCT07484724) | Shanghai Junshi Bioscience Co., Ltd. | 2026-04-13 |
| A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer (NCT07309276) | Shanghai Junshi Bioscience Co., Ltd. | 2026-01-23 |
| JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. (NCT07284134) | Shanghai Junshi Bioscience Co., Ltd. | 2025-12-24 |
| JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma (NCT07081022) | Shanghai Junshi Bioscience Co., Ltd. | 2025-08-17 |
| Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy (NCT06924606) | Shanghai Junshi Bioscience Co., Ltd. | 2025-07-15 |
| JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC (NCT06969027) | Shanghai Junshi Bioscience Co., Ltd. | 2025-06-19 |
| JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma (NCT06954467) | Shanghai Junshi Bioscience Co., Ltd. | 2025-05-29 |
| JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC (NCT06944470) | Shanghai Junshi Bioscience Co., Ltd. | 2025-05-20 |
| A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer (NCT06885385) | Shanghai Junshi Bioscience Co., Ltd. | 2025-04-23 |
| A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour (NCT06888830) | Shanghai Junshi Bioscience Co., Ltd. | 2025-04-11 |
| Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy (NCT06868836) | Shanghai Junshi Bioscience Co., Ltd. | 2025-03-30 |
| A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies (NCT06839105) | Shanghai Junshi Bioscience Co., Ltd. | 2025-02-21 |
| A Bioequivalence Study of JS005 Pre-filled Syringe and JS005 Auto-injector (NCT06732973) | Shanghai Junshi Bioscience Co., Ltd. | 2024-12-20 |
| A Clinical Study of JS005 in Patients With Ankylosing Spondylitis (NCT06250062) | Shanghai Junshi Bioscience Co., Ltd. | 2024-01-13 |
| A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) (NCT06170489) | Shanghai Junshi Bioscience Co., Ltd. | 2023-12-28 |
| A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors (NCT06139211) | Shanghai Junshi Bioscience Co., Ltd. | 2023-12-06 |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) (NCT06095583) | Shanghai Junshi Bioscience Co., Ltd. | 2023-11-15 |
| The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor (NCT06022250) | Shanghai Junshi Bioscience Co., Ltd. | 2023-09-26 |
| A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401 (NCT06041165) | Shanghai Junshi Bioscience Co., Ltd. | 2023-08-31 |
| A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis (NCT05975268) | Shanghai Junshi Bioscience Co., Ltd. | 2023-08-28 |
| Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study (NCT05342194) | Shanghai Junshi Bioscience Co., Ltd. | 2023-06-19 |
| A Pharmacokinetic Study of JS002 in Healthy Subjects (NCT05859529) | Shanghai Junshi Bioscience Co., Ltd. | 2023-05-30 |
| A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects (NCT06158737) | Shanghai Junshi Bioscience Co., Ltd. | 2023-05-10 |
| A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies (NCT05650203) | Shanghai Junshi Bioscience Co., Ltd. | 2023-03-31 |
| A Phase I Study Of JS015 in Patients With Advanced Solid Tumors (NCT05770310) | Shanghai Junshi Bioscience Co., Ltd. | 2023-02-13 |
| Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NCT05618327) | Shanghai Junshi Bioscience Co., Ltd. | 2023-02-13 |
| JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer (NCT05664971) | Shanghai Junshi Bioscience Co., Ltd. | 2023-02-09 |
| Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia (NCT05621070) | Shanghai Junshi Bioscience Co., Ltd. | 2023-02-03 |
| A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma (NCT04568304) | Shanghai Junshi Bioscience Co., Ltd. | 2022-09-06 |
| A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors (NCT05427396) | Shanghai Junshi Bioscience Co., Ltd. | 2022-07-28 |
| A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors (NCT05502393) | Shanghai Junshi Bioscience Co., Ltd. | 2022-07-26 |
| A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors (NCT05388279) | Shanghai Junshi Bioscience Co., Ltd. | 2022-04-28 |
| JS001+IMP4297 in Patients With Advanced Cancer (NCT05262842) | Shanghai Junshi Bioscience Co., Ltd. | 2022-03-29 |
| A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies (NCT05253105) | Shanghai Junshi Bioscience Co., Ltd. | 2022-03-15 |
| The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed Hyperlipidemia (NCT05532800) | Shanghai Junshi Bioscience Co., Ltd. | 2022-02-28 |
| A Study Explore JS001+JS002 in Patients With Advanced Cancer (NCT05128539) | Shanghai Junshi Bioscience Co., Ltd. | 2022-02-10 |
| PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer (NCT05180734) | Shanghai Junshi Bioscience Co., Ltd. | 2022-02-10 |
| A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH). (NCT05325203) | Shanghai Junshi Bioscience Co., Ltd. | 2021-12-31 |
| Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA (NCT05242588) | Shanghai Junshi Bioscience Co., Ltd. | 2021-12-31 |
| A Study of JS026 and JS026 Together With JS016 for Treatment of COVID-19 (NCT05167279) | Shanghai Junshi Bioscience Co., Ltd. | 2021-12-16 |
| Clinical Study of JS007 in Patients With Advanced Solid Tumors (NCT05049265) | Shanghai Junshi Bioscience Co., Ltd. | 2021-11-17 |
| Study of JS004 Combined With Toripalimab for Advanced Lung Cancer (NCT05000684) | Shanghai Junshi Bioscience Co., Ltd. | 2021-08-27 |
| Clinical Study of JS201 in Patients With Advanced Malignant Tumors (NCT04956926) | Shanghai Junshi Bioscience Co., Ltd. | 2021-07-29 |
| Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (NCT04848753) | Shanghai Junshi Bioscience Co., Ltd. | 2021-05-12 |
| The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC (NCT04929080) | Shanghai Junshi Bioscience Co., Ltd. | 2021-05-11 |
| Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. (NCT04797702) | Shanghai Junshi Bioscience Co., Ltd. | 2021-04-21 |
| The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor (NCT05061628) | Shanghai Junshi Bioscience Co., Ltd. | 2021-04-21 |
| A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors (NCT04773951) | Shanghai Junshi Bioscience Co., Ltd. | 2021-04-12 |
| A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer (NCT04856631) | Shanghai Junshi Bioscience Co., Ltd. | 2021-04-06 |
| Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS (NCT05212051) | Shanghai Junshi Bioscience Co., Ltd. | 2021-04-01 |
| Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing (NCT05344248) | Shanghai Junshi Bioscience Co., Ltd. | 2021-01-20 |
| The Safety and Efficacy of Multiple-dose of JS002 in Subject With Hyperlipidemia (NCT04781114) | Shanghai Junshi Bioscience Co., Ltd. | 2020-12-23 |
| JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects (NCT04780321) | Shanghai Junshi Bioscience Co., Ltd. | 2020-10-30 |
| Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC (NCT04723004) | Shanghai Junshi Bioscience Co., Ltd. | 2020-10-15 |
| Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer (NCT04394975) | Shanghai Junshi Bioscience Co., Ltd. | 2020-08-20 |
| To Evaluate the Efficacy and Safety of JS002 in HoFH Patients (NCT04515927) | Shanghai Junshi Bioscience Co., Ltd. | 2020-08-17 |
| A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China (NCT04477772) | Shanghai Junshi Bioscience Co., Ltd. | 2020-07-17 |
| Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC (NCT04523493) | Shanghai Junshi Bioscience Co., Ltd. | 2020-06-29 |
| Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects (NCT04441918) | Shanghai Junshi Bioscience Co., Ltd. | 2020-06-05 |
| Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers (NCT04220073) | Shanghai Junshi Bioscience Co., Ltd. | 2020-05-17 |
| Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies (NCT04278859) | Shanghai Junshi Bioscience Co., Ltd. | 2020-04-28 |
| A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) (NCT04605796) | Shanghai Junshi Bioscience Co., Ltd. | 2020-04-10 |
| Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC (NCT04158440) | Shanghai Junshi Bioscience Co., Ltd. | 2020-04-07 |
| Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) . (NCT04234620) | Shanghai Junshi Bioscience Co., Ltd. | 2020-02-15 |
| Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer (NCT04012606) | Shanghai Junshi Bioscience Co., Ltd. | 2019-07-23 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia.. (NCT04469673) | Shanghai Junshi Bioscience Co., Ltd. | 2019-05-23 |
| Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI (NCT03924050) | Shanghai Junshi Bioscience Co., Ltd. | 2019-05-06 |
| Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma (NCT03867370) | Shanghai Junshi Bioscience Co., Ltd. | 2019-04-26 |
| A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC (NCT03856411) | Shanghai Junshi Bioscience Co., Ltd. | 2019-03-18 |
| Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection (NCT03859128) | Shanghai Junshi Bioscience Co., Ltd. | 2019-03-05 |
| Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (NCT03829969) | Shanghai Junshi Bioscience Co., Ltd. | 2019-01-31 |
| Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (NCT04085276) | Shanghai Junshi Bioscience Co., Ltd. | 2018-12-21 |
| The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer (NCT03581786) | Shanghai Junshi Bioscience Co., Ltd. | 2018-10-18 |
| A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment (NCT03513666) | Shanghai Junshi Bioscience Co., Ltd. | 2018-04-09 |
| A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health Subjects (NCT04197817) | Shanghai Junshi Bioscience Co., Ltd. | 2017-12-11 |
| The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001 (NCT03301688) | Shanghai Junshi Bioscience Co., Ltd. | 2017-09-18 |